[1]Shan FL,Lu HK.Application progress of calcitonin in clinical diagnosis and treatment of medullary thyroid cancer[J].Medical Recapitulate,2017,23(2):240-248.[单凤玲,陆汉魁.血清降钙素在甲状腺髓样癌临床诊疗中的应用进展[J].医学综述,2017,23(2):240-248.]
[2]Wells SA Jr,Asa SL,Dralle H,et al.American Tyroid Association Guidelines Task Force on Medullary Tyroid Carcinoma.Revised American Thyroid Association guidelines for the management of medullary thyroid carcinomaa[J].Tyroid,2015,25(6):567-610.
[3]Pazaitou-Panayiotou K,Chrisoulidou A,Mandanas S,et al.Predictive factors that in uence the course of medullary thyroid carcinoma[J].Int J Clin Oncol,2014,19(3):445-451.
[4]Karagiannis AK,Giriofragkoulakis C,Nakouti T.Procalcitonin:A new biomarker for medullary thyroid cancer? A systematic review[J].Anticancer Research,2016,36(8):3803-3810.
[5]Niederle B.Screening for medullary carcinoma of the thyroid[J].Br J Surg,2014,101(13):1625-1626.
[6]Felsenfeld AJ,Levine BS.Calcitonin,the forgotten hormone:Does it deserve to be forgotten[J]?Clinical Kidney Journal,2015,8(2):180-187.
[7]Davey RA,Findlay DM.Calcitonin:Physiology or fantasy[J]?J Bone Miner Res,2013,28(5):973-979.
[8]Bevilacqua M,Dominguez LJ,Righini V,et al.Dissimilar PTH,gastrin,and calcitonin responses to oral calcium and peptones in hypocalciuric hypercalcemia,primary hyperparathyroidism,and normal subjects:a useful tool for differential diagnosis[J].J Bone Miner Res,2006,21(3):406-412.
[9]Trimboli P,Cremonini N,Ceriani L,et al.Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer:A retrospective multicentre study[J].Clin Endocrinol (oxf),2014,80:135-140.
[10]D Trimboli P,Giovannella L,Crescenzi A,et al.Medullary thyroid cancer diagnosis:an appraisal[J].Head Neck,2014,36:1216-1223.
[11]Rosario PW,Calsolari MR.Usefulness of serum calcitonin in patients without a suspicious history of medullary thyroid carcinoma and with thyroid nodules without an indication for fine-needle aspiration or with benign cytology[J].Hormone & Metabolic Research,2016,48(06):372-376.
[12]Rosario PW,Penna GC,Brandao K,et al.Usefulness of preoperative serum calcitonin in patients with nodular thyroid disease without suspicious history or cytology for medullary thyroid carcinoma[J].Arq Bras Endocrinol Metabol,2013,57(4):312-316.
[13]Trimboli P,Giovanella L.Serum calcitonin negative medullary thyroid carcinoma:a systematic review of the literature[J].Clinical Chemistry & Laboratory Medicine,2015,53(10):1507-1514.
[14]Gharib H,Papini E,Paschke R,et al.AACE/AMA/ETA Task Force on Thyroid Nodules.American Association of Clinical Endocrinologists,Associazione Medici Endocrinologi,and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules:Executive summary of recommendations[J].Endocr Pract,2010,16:468-475.
[15]Gibelin H,Essique D,Jones C,et al.Increased calcitonin level in thyroid nodules without medullary carcinoma [J].British Journal of Surgery,2005,92(5):574-578.
[16]Costante G,Meringolo D,Durante C,et al.Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5 817 consecutive patients with thyroid nodules[J].J Clin Endocrinol Metab,2007,92(2):450-455.
[17]Milone F,Ramundo V,Chiofalo MG,et al.Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels[J].Clinical Endocrinology,2010,73(1):85-88.
[18]Bae YJ,Schaab M,Kratzsch J.Calcitonin as biomarker for the medullary thyroid carcinoma[J].Recent Results in Cancer Research,2015,204:117-137.
[19]Trimboli P,Treglia G,Guidobaldi L,et al.Detection rate of FNA cytology in medullary thyroid carcinoma:A meta-analysis[J].Clinical Endocrinology,2015,82(2):280-285.
[20]Trimboli P,Nigri G,Romanelli F,et al.Medullary thyroid nodules by measurement of calcitonin (Ct) in aspiration needle washout in patients with multinodular goiter and moderately elevated serum Ct[J].Exp Clin Endocrinol Diabetes,2012,120:234-237.
[21]De Crea C,Raffaelli M,Maccora D,et al.Calcitonin measurement in fine-needle aspirate washouts vs cytologic examination for diagnosis of primary or metastatic medullary thyroid carcinoma[J].Acta Otorhinolaryngol Ital,2014,34:399-405.
[22]Algeciras-Schimnich A,Preissner CM,Theobald JP,et al.Procalcitonin:A marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma[J].Journal of Clinical Endocrinology & Metabolism,2009,94(3):861-868.
[23]Andreas Machens,Kerstin Lorenz,Henning Dralle.Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer[J].J Clin Endocrinol Metab,2014,99(8):2986-2994.
[24]Trimboli P,Seregni E,Treglia G,et al.Procalcitonin for detecting medullary thyroid carcinoma:a systematic review[J].Endocr Relat Cancer,2015,22(3):R157-164.
[25]Raue F,Frank-Raue K.Epidemiology and clinical presentation of medullary thyroid carcinoma[J].Recent Results in Cancer Research,2015,204:61-90.
[26]Machens A,Ukkat J,Hauptmann S,et al.Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression:a multivariate analysis[J].Archives of Surgery,2007,142(3):289-293.
[27]Camacho CP,Lindsey SC,Melo MCC,et al.Measurement of calcitonin and calcitonin gene-related peptide mRNA refines the management of patients with medullary thyroid cancer and may replace calcitonin-stimulation tests[J].Thyroid:Official Journal of the American Thyroid Association,2013,23(3):308-316.
[28]Wimalawansa SJ.CGRP radioreceptor assay:A new diagnostic tool for medullary thyroid carcinoma[J].Journal of Bone & Mineral Research,1993,8(4):467-473.
[29]Inaji H,Komoike Y,Motomura K,et al.Demonstration and diagnostic significance of pro-gastrin-releasing peptide in medullary thyroid carcinoma[J].Oncology,2000,59(2):122-125.
[30]Parra-Robert M,Orois A,Augé JM,et al.Utility of proGRP as a tumor marker in the medullary thyroid carcinoma[J].Clinical Chemistry & Laboratory Medicine,2016,55(3):441-446.
[31]Zhu W,Hai T,Ye L,et al.Medullary thyroid carcinoma cell lines contain a self-renewing CD133p population that is dependent on ret proto-oncogene activity[J].J Clin Endocrinol Metab,2010,95:439-444.
[32]Maliszewska A,Leandro-Garcia LJ,Castelblanco E,et al.Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions[J].Am J Pathol,2013,182:350-362.
[33]Bi Y,Meng Y,Wu H,et al.Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma:A ten-year follow-up and prognostic analysis[J].Journal of Surgical Oncology,2016,113(2):144-151.
[34]Pusztaszeri MP,Bongiovanni M,Faquin WC.Update on the cytologic and molecular features of medullary thyroid carcinoma[J].Advances in Anatomic Pathology,2014,21(1):31-40.
[35]Abraham D,Jackson N,Gundara JS,et al.MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis,prognosis,and potential therapeutic targets[J].Clin Cancer Res,2011,17:4772-4781.
[36]Hudson J,Duncavage E,Tamburrino A,et al.Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma[J].Experimental & Molecular Pathology,2013,95(1):62-67.
[37]Galuppini F,Bertazza L,Barollo S,et al.MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinical-pathological features and outcome[J].Virchows Archiv,2017,E2031:1-8.
[38]Chu YH,Hardin H,Schneider DF,et al.MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma[J].Experimental & Molecular Pathology,2017,103(2):229-236.
[39]Pennelli G,Galuppini F,Barollo S,et al.The PDCD4/miR-21 pathway in medullary thyroid carcinoma[J].Human Pathology,2015,46(1):50-57.
[40]Boichard A,Croux L,Al AG,et al.Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon[J].Journal of Clinical Endocrinology & Metabolism,2012,97(10):E2031-2035.
[41]Agrawal N,Jiao Y,Sausen M,et al.Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS[J].Journal of Clinical Endocrinology & Metabolism,2013,98(2):364-369.
[42]Moura MM,Cavaco BM,Leite V.RAS proto-oncogene in medullary thyroid carcinoma[J].Endocrine-related Cancer,2015,22(5):R235-252.